{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T07:40:39Z","timestamp":1792309239270,"version":"4.4.0"},"reference-count":49,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Vasc Access"],"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>Arteriovenous fistulas constitute an effective vascular access option for haemodialysis, demonstrating high patency rates and lower infection risk compared with synthetic accesses. Treatment algorithms and patient characteristics differ between haemodialysis and apheresis therapy, and fistula outcomes in patients receiving lipoprotein apheresis have not yet been systematically evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This single-centre, retrospective cohort study compared arteriovenous fistula outcomes in 29 patients receiving lipoprotein apheresis with those of 87 frequency-matched patients on haemodialysis. Matching criteria included age, sex, fistula configuration and diabetes mellitus status. Primary and secondary patency rates and associated risk factors were assessed over a 24-month follow-up period using Kaplan-Meier and Cox regression analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The study included patients with radiocephalic (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200972) or brachiocephalic (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200944) arteriovenous fistulas. Indications for apheresis were elevated lipoprotein(a) levels (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200926) and dyslipoproteinemia (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u20093). Mean age was comparable between groups (61.4 vs 61.2\u2009years), as was the proportion of male patients (58.6% vs 60.9%). Diabetes mellitus was present in 58.6% of apheresis patients and 49.4% of haemodialysis patients. Two-year primary patency rates were comparable between groups (49.2% vs 50.8%), while secondary patency was lower in the apheresis group (59.9% vs 71.1%). In the apheresis cohort, diabetes was associated with reduced primary (HR, 4.034; 95 % CI, 1.10\u201314.80;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.035) and secondary patency (HR, 9.807; 95 % CI, 1.24\u201377.59;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.030). Apheresis before fistula creation demonstrated improved secondary patency (HR, 0.198; 95% CI, 0.04\u20130.94;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.042). In haemodialysis patients, hyperlipoproteinemia was associated with reduced secondary patency (HR, 2.28; 95% CI, 1.01\u20135.14;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.046).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Arteriovenous fistula patency in patients undergoing apheresis was comparable to haemodialysis patients despite elevated lipoprotein levels. Diabetes was associated with reduced fistula patency in lipoprotein apheresis. The findings support arteriovenous fistulas as long-term access option and highlight the importance of individualised access planning.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/11297298261493241","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T05:38:02Z","timestamp":1792042682000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of arteriovenous fistula patency in lipoprotein apheresis and haemodialysis: A matched case-control study"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-7243-2973","authenticated-orcid":false,"given":"Julius","family":"Spilles","sequence":"first","affiliation":[{"name":"Department of General, Visceral and Vascular Surgery, Jena University Hospital, Friedrich Schiller University Jena, Jena, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andree","family":"Klemm","sequence":"additional","affiliation":[{"name":"KfH Kidney Center for Dialysis and Kidney Transplantation e.V., Jena, Thuringia, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Utz","family":"Settmacher","sequence":"additional","affiliation":[{"name":"Department of General, Visceral and Vascular Surgery, Jena University Hospital, Friedrich Schiller University Jena, Jena, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Zanow","sequence":"additional","affiliation":[{"name":"Department of General, Visceral and Vascular Surgery, Jena University Hospital, Friedrich Schiller University Jena, Jena, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9237-1321","authenticated-orcid":false,"given":"Stefan","family":"Ludewig","sequence":"additional","affiliation":[{"name":"Department of General, Visceral and Vascular Surgery, Jena University Hospital, Friedrich Schiller University Jena, Jena, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,10,14]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2019.12.001"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2008.08.044"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0741-5214(03)00426-9"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2002.kid551.x"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2001.00947.x"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(12)80672-X"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2016.01.053"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2013.08.023"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejvs.2017.06.024"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/jca.22043"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(81)91213-7"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-019-0787-5"},{"issue":"8934","key":"e_1_3_2_14_2","first-page":"1383","volume":"344","author":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","year":"1994","unstructured":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344(8934): 1383\u20131389.","journal-title":"Lancet"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1063"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2009.12.036"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.002432"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehq386"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9150(98)00328-1"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.116.307983"},{"issue":"3","key":"e_1_3_2_21_2","first-page":"229","article-title":"Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events","volume":"6","author":"Jaeger BR","year":"2009","unstructured":"Jaeger BR, Richter Y, Nagel D, et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med 2009; 6(3): 229\u2013239.","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1161\/ATV.0000000000000177"},{"issue":"1","key":"e_1_3_2_23_2","first-page":"16","article-title":"Lipoprotein apheresis: first FDA indicated treatment for elevated lipoprotein(a)","volume":"1","author":"Nugent A","year":"2020","unstructured":"Nugent A, Gray J, Gorby L, et al. Lipoprotein apheresis: first FDA indicated treatment for elevated lipoprotein(a). J Clin Cardiol 2020; 1(1): 16\u201321.","journal-title":"J Clin Cardiol"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-026-04750-2"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosissup.2019.08.038"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2013.11.002"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1067\/mva.2002.122025"},{"key":"e_1_3_2_28_2","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Kidney Disease: Improving Global Outcomes CKDWG","year":"2024","unstructured":"Kidney Disease: Improving Global Outcomes CKDWG. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 2024; 105(4S): S117\u2013S314.","journal-title":"Kidney Int"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2008.09.003"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00730112"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/trf.14479"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.5301\/jva.5000644"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/1744-9987.13799"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0741-5214(98)70302-7"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2018.10.063"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.34067\/KID.0000462020"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.2002.29886"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.1999.00515.x"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.V781169"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1177\/11297298211054634"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.02950707"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1024\/0301-1526\/a000018"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1080\/0886022X.2018.1456464"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2024.100940"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1097\/MOL.0000000000000753"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1177\/112972980700800208"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1177\/1708538120905486"},{"issue":"1","key":"e_1_3_2_48_2","first-page":"18","article-title":"Rosuvastatin failed to improve arteriovenous fistula patency for hemodialysis in diabetic patients - a randomized clinical trial","volume":"37","author":"Roan JN","year":"2021","unstructured":"Roan JN, Lin WH, Tsai MT, et al. Rosuvastatin failed to improve arteriovenous fistula patency for hemodialysis in diabetic patients - a randomized clinical trial. Acta Cardiol Sin 2021; 37(1): 18\u201329.","journal-title":"Acta Cardiol Sin"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1177\/11297298221115557"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2014.06.092"}],"container-title":["The Journal of Vascular Access"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11297298261493241","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/11297298261493241","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11297298261493241","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T07:18:17Z","timestamp":1792307897000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/11297298261493241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,14]]},"references-count":49,"alternative-id":["10.1177\/11297298261493241"],"URL":"https:\/\/doi.org\/10.1177\/11297298261493241","relation":{},"ISSN":["1129-7298","1724-6032"],"issn-type":[{"value":"1129-7298","type":"print"},{"value":"1724-6032","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,14]]},"article-number":"11297298261493241"}}